GMOV - ETF AI Analysis
Top Page
GMO US Value ETF (GMOV)
Rating:73Outperform
Price Target:―
Positive Factors
Broad Sector Diversification
The ETF spreads its investments across many sectors, which helps reduce the impact if any one industry runs into trouble.
Overall Strong Recent Performance
The fund has delivered strong gains so far this year and in recent months, suggesting its value-focused approach has been working recently.
Solid Contributions from Key Holdings
Several major positions in areas like energy, health care, consumer staples, and financials have shown strong performance, supporting the fund’s returns.
Negative Factors
High U.S. Market Concentration
Almost all of the ETF’s assets are invested in U.S. companies, offering little geographic diversification if the U.S. market weakens.
Notable Weakness in Some Top Tech Holdings
Large positions in major technology names have shown weak performance recently, which can drag on the fund despite strength elsewhere.
Moderate Expense Ratio
The fund’s fees are not especially low, which means a noticeable slice of returns goes toward costs each year.
GMOV vs. SPDR S&P 500 ETF (SPY)
AUM99.09M
RegionNorth America
Expense Ratio0.50%
Beta0.69
IssuerGMO
Inception DateOct 28, 2024
Dividend Yield1.83%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume32,148
30 Day Avg. Volume17,980
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.67Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering165
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GMOV Summary
GMOV, the GMO US Value ETF, invests in a wide range of U.S. companies with a focus on “value” stocks—businesses the managers believe are currently priced lower than what they’re really worth. It doesn’t track a specific index, but follows a value theme across the total U.S. market, holding well-known names like Microsoft and Meta Platforms, along with banks, health care, energy, and more. Someone might invest in GMOV to seek long-term growth while staying diversified across many sectors. A key risk is that value stocks can stay out of favor for long periods, so the share price can rise and fall with market swings.
How much will it cost me?The GMO US Value ETF (GMOV) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, relying on expert analysts to select undervalued stocks with strong growth potential.
What would affect this ETF?The GMO US Value ETF could benefit from a favorable economic environment that supports undervalued stocks, particularly in sectors like Financials and Health Care, which are heavily represented in its portfolio. However, rising interest rates or regulatory changes in key sectors such as Technology and Energy could negatively impact the ETF's performance. Additionally, shifts in consumer spending or market sentiment might influence the value of top holdings like Johnson & Johnson and Meta Platforms.
GMOV Top 10 Holdings
GMOV leans heavily into U.S. value names, with a clear tilt toward big tech, health care, and financials. Microsoft is one of the main engines, still rising on the back of cloud and AI strength, while Meta has been more of a wobbling wheel lately, with mixed sentiment weighing on returns. On the defensive side, Merck, Johnson & Johnson, and Bristol-Myers are steady climbers, helping smooth out volatility. Exxon Mobil adds an energy kicker, and banks like JPMorgan and Bank of America provide traditional value ballast, keeping the fund firmly anchored in the U.S. market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Microsoft | 7.00% | $6.89M | $3.64T | -3.90% | 79 Outperform | |
| Meta Platforms | 6.31% | $6.22M | $1.72T | -12.55% | 76 Outperform | |
| Exxon Mobil | 3.83% | $3.77M | $671.56B | 43.31% | 74 Outperform | |
| Verizon | 2.65% | $2.61M | $206.74B | 10.67% | 81 Outperform | |
| Merck & Company | 2.52% | $2.48M | $357.52B | 80.48% | 80 Outperform | |
| JPMorgan Chase | 2.49% | $2.45M | $927.49B | 11.52% | 72 Outperform | |
| Pfizer | 2.35% | $2.31M | $156.51B | 14.45% | 74 Outperform | |
| Bank of America | 2.08% | $2.05M | $404.88B | 11.60% | 72 Outperform | |
| Bristol-Myers Squibb | 2.03% | $2.00M | $129.92B | 39.58% | 78 Outperform | |
| Qualcomm | 1.97% | $1.94M | $194.13B | 12.24% | 80 Outperform |
GMOV Technical Analysis
Positive
―
Price Trends
32.10
Positive
30.98
Positive
29.53
Positive
Market Momentum
0.13
Positive
44.70
Neutral
10.53
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GMOV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.76, equal to the 50-day MA of 32.10, and equal to the 200-day MA of 29.53, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 10.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GMOV.
GMOV Peer Comparison
Comparison Results
Performance Comparison
GMOV
GMO US Value ETF
32.25
6.36
24.57%
VUSV
Vanguard Wellington U.S. Value Active ETF
―
―
―
SASS
M.D. Sass Concentrated Value ETF
―
―
―
CVAR
Cultivar ETF
―
―
―
GVLE
Goldman Sachs Value Opportunities ETF
―
―
―
USFE
First Eagle US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents